In different skin models, key receptors could be identified whose modulation can help in creating compromised-skin topicals against SARS-CoV-2 entry.
According to studies, more than two-thirds of schoolchildren have headaches on a regular basis. Around 20% of children and adolescents repeatedly miss lessons as a result.
The assessment of a novel anti-OX40 antibody resulted in substantial reductions in Eczema Area and Severity Index scores in a recent trial.
A study published in JAMA investigated whether adding antithrombotic therapy to placebo reduced major cardiopulmonary complications over a 45-day treatment period in COVID-19 outpatients.
For atopic dermatitis with less than 10% body surface area involvement, difelikefalin has exhibited significant efficacy in itch reduction.
A study linked genital warts and human leukocyte antigen systems. Protective and risk alleles could be identified as future antiviral or vaccine targets.
A dose-ranging study showed that oral treatment with the JAK3 inhibitor ritlecitinib is efficacious in reducing depigmented areas in the face.
A elderly-focused subanalysis of phase 3 trials revealed IGA-TS in 60.5% of atopic dermatitis patients applying 1.5% ruxolitinib cream over 8 weeks.
What influence do cardiological, social or neurological problems have on psychiatric diseases and vice versa? This question was addressed by the speakers at the symposium "Recognising and treating psychiatric comorbidities".
A trial showed abrocitinib superiority over dupilumab in fast itch control and skin clearance in adult patients with moderate-to-severe atopic dermatitis.
A long-term assessment of topical tapinarof found a high rate of complete disease clearance as well as a lasting response up to 52 weeks.
Ritlecitinib was able to induce regrowth of hair in the ALLEGRO study. The effect was seen even in patients with alopecia universalis.
Two phase 3 trials have demonstrated the efficacy of the topical JAK1/JAK2 inhibitor ruxolitinib in the therapy of vitiligo. The cream was well tolerated.
The physician-patient relationship has been going through a profound crisis for years, with consequences not only for individual health but also for public health. We met with Prof. Fabrizio Asioli to talk about the issue.
The once-daily deucravacitinib showed maintenance of response through week 52 in phase 3 POETYK PSO-1 and POETYK PSO-2 trials.
A registry study revealed no differences in respiratory tract infections risks across biologics, including the newer IL-17 and IL-23 inhibitors.
Remibrutinib showed promise with early-onset and further maintained action in chronic spontaneous urticaria, with many reaching a well-controlled disease.
A trial that compared upadacitinib with dupilumab in adults with moderate-to-severe AD demonstrated benefits in shifting to the inhibitor.
In a phase 2a atopic dermatitis study, maintenance of response continued for months after last dose; this may hint at an option for extended medication intervals.
Advice, words of encouragement and ideas for self-care from an experienced emergency physician to the younger generation.